Amgen just announced it will buy Onyx pharmaceuticals for $125 per share in a deal that has been brewing since June. The total value of the deal is $10.4 billion and it has no FX implications since both companies are based in California.
At times, M&A can indicate upbeat sentiment in stock markets and the global economy but pharma is its own little world, so I would be hesitant to read anything into this tie-up.
